Creating therapies for Alzheimer's disease by targeting neural circuits

November 10, 2016 by Helen Knight, Massachusetts Institute of Technology
Beta-amyloid plaque deposits (red) disrupt mylelin (green) organization in the brain and activate microglia (orange), driving the inflammation, neurodegeneration, and cognitive disfunction associated with Alzheimer's disease. Credit: Rebecca Canter

Age-related dementia will affect 10 percent of people in the U.S. within their lifetime.

Alzheimer's disease, the most prevalent type of dementia—and one for which there is no effective treatment or cure—causes a progressive and devastating loss of memory and cognition.

For the past 25 years, efforts to develop a treatment for the disease have focused on the so-called "amyloid cascade hypothesis." This proposes that amyloid-β (Aβ) peptides build up and clump together to form plaques in the , creating a cascade effect that ultimately leads to neuronal death and cognitive dysfunction.

However, despite evidence of a link between amyloid-β and Alzheimer's disease, efforts to target the peptide have so far failed to reverse this cognitive decline.

Now, in a review paper published in the journal Nature, researchers at the Picower Institute for Learning and Memory at MIT argue that while elevated amyloid-β levels may initiate the sequence of events that lead to the disease, a complex series of other molecular, cellular, circuit and network-level changes contribute to its progression. What's more, the researchers argue, these changes cannot be reversed simply by controlling amyloid-β levels.

Many of the treatments designed to target amyloid-β use antibodies to clear plaque from the brain, and are very effective in doing so, according to Li-Huei Tsai, the Picower Professor of Neuroscience and director of the Picower Institute for Learning and Memory at MIT.

"But these clinical trials fail because patients don't show improvement in cognitive function," Tsai says. "So there is a disconnection there, in that when you clear the amyloid-β, you still don't see the positive outcome that you are expecting."

This is underscored by observations indicating that levels of amyloid-β in the brain appear to stop increasing relatively early in the disease's progression, when cognitive impairment is still mild, she says.

"Amyloid-β starts to build up in the brain 20 years or more before the person starts to show clinical symptoms, and at some point the levels plateau, and the person can still be functionally normal."

What is needed is a greater understanding of how the circuitry of the brain responds to the initial increase in amyloid-β levels, and how the plaques influence the brain's network activity over time, including its connections, circuits, and information processing, she says.

Credit: Massachusetts Institute of Technology

Studies have shown that amyloid-β accumulates significantly in an area of the brain known as the , a group of connected regions that are active during thinking, remembering, and planning.

Research has also shown that levels of amyloid-β are closely linked to neuronal activity. Blocking leads to a decrease in amyloid-β, for example, while increased activity raises levels of the peptide, researchers have found.

"However, at a more detailed mapping level, we still don't know in which circuit or brain region amyloid-β starts to build up, how it propagates from one region to the next, and how brain activity may regulate its propagation," Tsai says. "So these are all very important questions that the field still has to address."

Understanding which areas of the brain are initially affected by amyloid-β would help researchers to better target potential treatments, according to Jay Penney, a postdoc in Tsai's laboratory who co-authored the paper alongside Tsai and graduate student Rebecca Canter.

For example, the only treatments for the disease that have so far been approved by the FDA target specific neurotransmitter systems within the brain, and although these show only limited effect, they demonstrate that altering circuit or network activity has the potential to reduce cognitive dysfunction.

Small-scale human studies using deep-brain stimulation have also shown promising results in improving cognition.

Better understanding the early parts of the brain that are affected by amyloid-β and other types of pathology that develop in Alzheimer's might inform researchers of where to look for initial signs of the developing disease, Penney says.

"That could potentially allow us to start treatments that target the original cause of the pathology for instance, and reduce amyloid-β levels earlier, and then simultaneously we could also target specific circuits or brain regions, to hopefully improve cognitive function," he says.

It would also allow clinicians to identify people at risk of the disease before they develop any , he says.

Although efforts to target amyloid as a therapy for Alzheimer's are ongoing, many experts believe this is most likely to succeed in the very early, preclinical, stages of the disease, prior to the onset of symptoms or when symptoms are very mild, according to Brad Dickerson, an associate professor of neurology at Harvard Medical School, who was not involved in the research.

"In the more than 5 million Americans with Alzheimer's disease dementia, we desperately need better treatments to improve symptoms and to slow progression," Dickerson says. "The variety of approaches discussed here highlight some of the broad portfolio of ideas that are being pursued."

Explore further: Is a marker of preclinical Alzheimer's disease associated with loneliness?

More information: Rebecca G. Canter et al. The road to restoring neural circuits for the treatment of Alzheimer's disease, Nature (2016). DOI: 10.1038/nature20412

Related Stories

Is a marker of preclinical Alzheimer's disease associated with loneliness?

November 2, 2016
A new article published online by JAMA Psychiatry used data from a study of 79 cognitively normal adults to examine whether cortical amyloid levels in the brain, a marker of preclinical Alzheimer disease, was associated with ...

'Pac-Man' gene implicated in Alzheimer's disease

July 26, 2016
A gene that protects the brain from the harmful build-up of amyloid-beta, one of the causative proteins implicated in Alzheimer's disease, has been identified as a new target for therapy by NeuRA researchers.

Dementia plaques attack language center of brain

March 7, 2016
The recent ability to peer into the brain of living individuals with a rare type of language dementia, primary progressive aphasia (PPA), provides important new insights into the beginning stages of this disease—which results ...

Promising new methods for early detection of Alzheimer's disease

July 8, 2016
New methods to examine the brain and spinal fluid heighten the chance of early diagnosis of Alzheimer's disease. Results from a large European study, led by researchers at the Karolinska Institutet, are now published in the ...

Can amyloid plaque in Alzheimer's disease affect remote regions of the brain?

July 21, 2014
In Alzheimer's disease, accumulation of amyloid plaque in the brain is believed to play an important role in many characteristic disease symptoms, including memory loss and other mental state changes. But how these plaque ...

New approaches to understanding Alzheimer's and Parkinson's disease

July 26, 2016
In a study presented today at the Alzheimer's Association International Conference 2016, researchers at the Douglas Mental Health University Institute have explored how some people may develop the hallmarks of Alzheimer's ...

Recommended for you

Alzheimer's disease: Neuronal loss very limited

January 17, 2018
Frequently encountered in the elderly, Alzheimer's is considered a neurodegenerative disease, which means that it is accompanied by a significant, progressive loss of neurons and their nerve endings, or synapses. A joint ...

Anxiety: An early indicator of Alzheimer's disease?

January 12, 2018
A new study suggests an association between elevated amyloid beta levels and the worsening of anxiety symptoms. The findings support the hypothesis that neuropsychiatric symptoms could represent the early manifestation of ...

One of the most promising drugs for Alzheimer's disease fails in clinical trials

January 11, 2018
To the roughly 400 clinical trials that have tested some experimental treatment for Alzheimer's disease and come up short, we can now add three more.

Different disease types associated with distinct amyloid-beta prion strains found in Alzheimer's patients

January 9, 2018
An international team of researchers has found different disease type associations with distinct amyloid-beta prion strains in the brains of dead Alzheimer's patients. In their paper published in Proceedings of the National ...

Advances in brain imaging settle debate over spread of key protein in Alzheimer's

January 5, 2018
Recent advances in brain imaging have enabled scientists to show for the first time that a key protein which causes nerve cell death spreads throughout the brain in Alzheimer's disease - and hence that blocking its spread ...

Molecular mechanism behind HIV-associated dementia revealed

January 5, 2018
For the first time, scientists have identified and inhibited a molecular process that can lead to neurodegeneration in patients with HIV, according to a Northwestern Medicine study published in Nature Communications.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.